Mitsubishi UFJ Trust and Banking Corporation, headquartered in Tokyo, Japan, is a prominent financial institution that offers a comprehensive range of services including banking and asset management. Established in 1927, the firm manages investment accounts primarily for pension funds and operates in both public equity and fixed income markets globally. Its investment strategy encompasses growth and value-oriented investments in small-cap and mid-cap companies, as well as floating rate bonds for domestic fixed income portfolios. The firm also engages in alternative investments, focusing on real estate and private equity, employing a long-short strategy and utilizing both qualitative and quantitative analyses. Additionally, Mitsubishi UFJ Trust and Banking Corporation emphasizes socially responsible investments and serves a diverse clientele through its extensive network of branches and subsidiaries across Asia, Europe, and the United States. As a wholly owned subsidiary of Mitsubishi UFJ Financial Group, it plays a vital role in the group's overall operations and strategy.
First Sentier Investors, a subsidiary of First State Investment Management (UK) Limited, is a prominent asset management firm that operates under the umbrella of the Commonwealth Bank of Australia. With approximately €130 billion in global investments, it has established itself as a leading manager and investor in infrastructure assets. The firm boasts over twenty years of experience in this sector, making it one of the longest-standing managers for institutional investors. Currently, First Sentier Investors manages over €4.8 billion in equity across various infrastructure assets, including utilities, transportation, and social infrastructure, primarily within Australasia and Europe.
Synspective Inc., based in Tokyo, Japan, specializes in satellite data technology that integrates synthetic aperture radar (SAR) satellite constellations, big data, and machine learning. The company offers remote sensing and satellite imagery services using small-sized SAR satellites, which can monitor human activity across vast areas regardless of time or weather conditions. Its technology is designed to support various sectors, including urban design, infrastructure, energy, insurance, and finance, helping clients meet their sustainable development and resilient urban development objectives. Synspective stands out with its high frequency, resolution, and responsiveness in satellite data provision.
Point Nine offers middle and back office services to Financial Institutions. Their operations team, combined with their proprietary developed web-based operations platform, help their clients to complement their existing middle and back office operations or even become their complete one-stop middle and back office solution.
ORPHE TRACK is a smart shoes platform that helps urban runners achieve their specific goals, as it enables a detailed review of user's running routine without any extra measurement equipment . Their latest crowdfunding campaign has been very successful on gathering early adopters concerned about their physical exercise improvements: https://www.makuake.com/project/evoride-orphe/ The startup provides customized experiences to be used not only for wellness but also for healthcare - both disease prevention and early detection.
SanBio Company Limited is a regenerative medicine firm based in Tokyo, Japan, focused on developing and commercializing cell-based therapies for various central nervous system disorders. The company is advancing its lead product, SB623, currently in Phase II clinical trials for treating chronic motor deficits caused by traumatic brain injury and stroke. SanBio's research pipeline also includes SB618 for peripheral nerve damage, SB308 for muscular dystrophy, and other products targeting conditions such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, spinal cord injuries, and Alzheimer’s disease. Collaborations with several academic institutions and partners, such as Asahikawa Medical University and Juntendo University, support the development of these therapies. Founded in 2001, SanBio aims to address unmet medical needs through innovative regenerative medicine solutions.
SanBio Company Limited is a regenerative medicine firm based in Tokyo, Japan, focused on developing and commercializing cell-based therapies for various central nervous system disorders. The company is advancing its lead product, SB623, currently in Phase II clinical trials for treating chronic motor deficits caused by traumatic brain injury and stroke. SanBio's research pipeline also includes SB618 for peripheral nerve damage, SB308 for muscular dystrophy, and other products targeting conditions such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, spinal cord injuries, and Alzheimer’s disease. Collaborations with several academic institutions and partners, such as Asahikawa Medical University and Juntendo University, support the development of these therapies. Founded in 2001, SanBio aims to address unmet medical needs through innovative regenerative medicine solutions.
Rydex Fund Services
Acquisition in 2016
Rydex Fund Services, Inc. provides transfer agency, accounting, compliance, and information technology services for the Rydex funds. The company was formerly known as PADCO Service Company Inc. and changed its name to Rydex Fund Services, Inc. in December, 2000.
Developer and manufacturer of solar cells based in Tokyo. The company develops synthetic quartz-based solar cells by using synthetic quartz which are of two types, one is a colorless, transparent type and the other is a type that can generate electricity with extremely low illuminance.
Money Forward is a financial technology company that offers a range of services for individuals and corporations. It provides online personal accounting solutions that enable users to manage daily expenses by integrating data from bank accounts and credit cards. The platform is accessible on both desktop and mobile devices, including iOS and Android. In addition to personal financial management tools, Money Forward has developed a suite of cloud-based services tailored for businesses, which includes accounting software, tax return preparation, invoice management, payroll processing, and payment reconciliation. The company also engages users through economic media and an automatic savings app, as well as offering a communication channel where customers can interact with financial planners to address their financial concerns.
Solasia Pharma K.K. is a Tokyo-based pharmaceutical company that specializes in developing and distributing oncology therapies and cancer care products across Asia. The company offers episil oral liquid, designed to manage pain, and Sancuso, a transdermal system that administers granisetron to mitigate chemotherapy-induced nausea and vomiting. Additionally, Solasia is advancing its pipeline with SP-02, a mitochondrial-targeted agent currently in Phase II clinical trials for treating various hematologic and solid cancers, and SP-04, which has completed Phase IIb trials aimed at addressing chemotherapy-induced peripheral neuropathy. Established in 2006, Solasia Pharma is committed to improving cancer treatment options in the region.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.